GGTA1 KO Thymokidney
PreclinicalBiologic
United TherapeuticsGGTA1 KO Thymokidney is one of 49 biologic programs targeting ESRD. It is currently in Preclinical.
2
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
130 competitors in Safety and Efficacy
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Actemra
RochePhase 3
Humira
RRanbaxy Laboratories Limited
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Empaveli
Apellis PharmaceuticalsPhase 3
CAB LA
GSKPhase 3
Cytosar
TevaPhase 2
B/F/TAF
GileadPhase 3
Selzentry
GSKPhase 2
Nuzyra
PParatek Pharmaceuticals Inc
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GGTA1 KO Thymokidney. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company